Scope of this summary
Adults in the menopause transition or postmenopause seeking assessment of vasomotor, sleep, mood, sexual or genitourinary symptoms. This summary does not use hormone therapy to prevent chronic disease, does not provide product dosing and requires separate oncology input for hormone-sensitive cancer histories.
The Bottom Line
- Diagnose a typical menopause transition clinically from age, menstrual change and symptoms; investigate pregnancy, thyroid disease, anemia, medication effects or another cause when the presentation is atypical.
- Hormone therapy is the most effective treatment for bothersome vasomotor symptoms and also prevents bone loss, but route, formulation, duration and need for endometrial protection must be individualized.
- For healthy symptomatic patients younger than 60 years or within ten years of menopause onset, the benefit鈥搑isk balance is generally favorable when contraindications have been assessed.
- Use evidence-supported nonhormone options when hormone therapy is contraindicated or unwanted; do not present unregulated supplements as equivalent to therapies evaluated by The Menopause Society.
- Treat genitourinary syndrome directly and reassess vaginal, urinary and sexual symptoms rather than assuming systemic vasomotor treatment will address every complaint.
Practical clinical workflow
1
Document bleeding pattern, last menstrual period, vasomotor burden, sleep, mood, migraine, sexual and urinary symptoms, pregnancy possibility, cancer history, thrombosis, cardiovascular disease and medicines.
2
Measure blood pressure and complete examination or targeted tests only when the history creates a clinical question; unexplained bleeding requires evaluation before systemic hormone treatment.
3
Discuss hormone and nonhormone choices using absolute health risks, symptom priorities, uterus status, route preferences, cost and the patient鈥檚 willingness to revisit treatment.
4
Start the lowest effective individualized regimen, ensure a patient with a uterus has adequate endometrial protection when systemic estrogen is used, and schedule review of response and adverse effects.
5
Reassess periodically rather than applying an automatic age cutoff; continuation after age 65 can be reasonable for persistent indications with documented shared decision-making and risk mitigation.
Safety boundaries and escalation
- Postmenopausal bleeding, a pelvic mass, severe new headache, chest pain, unilateral leg swelling or focal neurologic symptoms requires prompt diagnostic assessment rather than routine symptom escalation.
- Systemic hormone therapy requires particular caution or avoidance with unexplained bleeding, estrogen-sensitive malignancy, prior thromboembolism, stroke, myocardial infarction or significant liver disease.
- Compounded bioidentical products lack the same evidence and regulatory oversight as approved products and should not be described as safer merely because they are marketed as natural.
- Nonhormone medicines have their own interaction, blood-pressure, liver, sedation and withdrawal considerations; verify the current FDA label before prescribing.
Localization
This US summary follows The Menopause Society position statements and current FDA-approved options. Product availability, insurance coverage and state scope rules vary.
Source documents
Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.
- The North American Menopause Society (now The Menopause Society)The 2022 hormone therapy position statement of The North American Menopause SocietyDOI 10.1097/GME.0000000000002028 路 published 2022-07-01 路 accessed 2026-08-20view source
- The North American Menopause Society (now The Menopause Society)The 2023 nonhormone therapy position statement of The North American Menopause SocietyDOI 10.1097/GME.0000000000002200 路 published 2023-06-01 路 accessed 2026-08-20view source
continue the learning
From guidance to deliberate practice and evidence
Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.
Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.